2017
DOI: 10.1111/den.12851
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of morbidity and mortality associated with endoscopic ultrasound‐guided fine‐needle aspiration for pancreatic cystic lesions: A systematic review and meta‐analysis

Abstract: EUS-FNA is a safe procedure for diagnosis of PCL and is associated with a relatively low incidence of adverse events. Most adverse events were mild, self-limiting, and did not require medical intervention.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

4
70
0
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 81 publications
(77 citation statements)
references
References 50 publications
4
70
0
3
Order By: Relevance
“…Endoscopic ultrasound‐FNA of cystic fluid from pancreatic cysts has been carried out to differentiate between malignant and benign lesions and between mucinous and non‐mucinous cysts . EUS‐FNA has been recommended for pancreatic cysts >15 mm in size .…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Endoscopic ultrasound‐FNA of cystic fluid from pancreatic cysts has been carried out to differentiate between malignant and benign lesions and between mucinous and non‐mucinous cysts . EUS‐FNA has been recommended for pancreatic cysts >15 mm in size .…”
Section: Methodsmentioning
confidence: 99%
“…Endoscopic ultrasound-FNA of cystic fluid from pancreatic cysts has been carried out to differentiate between malignant and benign lesions and between mucinous and nonmucinous cysts. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] EUS-FNA has been recommended for pancreatic cysts >15 mm in size. 13 Adverse events of EUS-FNA included bleeding in 0.2-6% of patients and infections in 0.2-5%.…”
Section: Endoscopic Ultrasound-guided Fine-needle Aspirationmentioning
confidence: 99%
“…FNA itself also has a certain risk of adverse events. A meta‐analysis of 40 articles evaluating morbidity and mortality associated with EUS‐FNA for PCL showed overall morbidity of 2.66% (95% CI, 1.84–3.62) and associated mortality of 0.19% (95% CI, 0.09–0.32) and also showed common post‐procedure adverse events including pancreatitis (0.92%, 95% CI, 0.63–1.28), hemorrhage (0.69%, 95% CI: 0.42–1.02), pain (0.49%, 95% CI: 0.27–0.79%), infection (0.44%, 95% CI: 0.27–0.66), desaturation (0.23%, 95% CI: 0.12–0.38) and perforation (0.21%, 95% CI: 0.11–0.36%) . The overall adverse event rate was relatively low; however, most studies did not include long term follow‐up data.…”
Section: Eus‐fna For Differential Diagnosis and Detection Of Malignanmentioning
confidence: 99%
“…Although EUS‐FNA is recommended in PCL with worrisome features, it is rarely carried out in Japan because of the risk of dissemination. However, it all comes down to the risk and benefit balances . There is a risk of peritoneal dissemination, albeit low, in EUS‐FNA for any lesions, either solid or cystic.…”
mentioning
confidence: 99%
“…However, it all comes down to the risk and benefit balances. 10 There is a risk of peritoneal dissemination, albeit low, in EUS-FNA for any lesions, either solid or cystic. However, if the diagnostic yield is high enough and clinical management changes according to the results of EUS-FNA, or EUS-TTNB, it should be the standard of care for the diagnosis of PCL.…”
mentioning
confidence: 99%